Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Connection

Karl Bayer to Calcium

This is a "connection" page, showing publications Karl Bayer has written about Calcium.

 
Connection Strength
 
 
 
2.586
 
  1. Rumian NL, Freund RK, Dell'Acqua ML, Coultrap SJ, Bayer KU. Decreased nitrosylation of CaMKII causes aging-associated impairments in memory and synaptic plasticity in mice. Sci Signal. 2023 07 25; 16(795):eade5892.
    View in: PubMed
    Score: 0.549
  2. Coultrap SJ, Bayer KU. Nitric oxide induces Ca2+-independent activity of the Ca2+/calmodulin-dependent protein kinase II (CaMKII). J Biol Chem. 2014 Jul 11; 289(28):19458-65.
    View in: PubMed
    Score: 0.290
  3. Barcomb K, Buard I, Coultrap SJ, Kulbe JR, O'Leary H, Benke TA, Bayer KU. Autonomous CaMKII requires further stimulation by Ca2+/calmodulin for enhancing synaptic strength. FASEB J. 2014 Aug; 28(8):3810-9.
    View in: PubMed
    Score: 0.290
  4. Coultrap SJ, Barcomb K, Bayer KU. A significant but rather mild contribution of T286 autophosphorylation to Ca2+/CaM-stimulated CaMKII activity. PLoS One. 2012; 7(5):e37176.
    View in: PubMed
    Score: 0.253
  5. Coultrap SJ, Buard I, Kulbe JR, Dell'Acqua ML, Bayer KU. CaMKII autonomy is substrate-dependent and further stimulated by Ca2+/calmodulin. J Biol Chem. 2010 Jun 04; 285(23):17930-7.
    View in: PubMed
    Score: 0.218
  6. Brown CN, Bayer KU. Studying CaMKII: Tools and standards. Cell Rep. 2024 04 23; 43(4):113982.
    View in: PubMed
    Score: 0.144
  7. Bayer KU, De Koninck P, Schulman H. Alternative splicing modulates the frequency-dependent response of CaMKII to Ca(2+) oscillations. EMBO J. 2002 Jul 15; 21(14):3590-7.
    View in: PubMed
    Score: 0.128
  8. Tullis JE, Rumian NL, Brown CN, Bayer KU. The CaMKII K42M and K42R mutations are equivalent in suppressing kinase activity and targeting. PLoS One. 2020; 15(7):e0236478.
    View in: PubMed
    Score: 0.111
  9. Chalmers NE, Yonchek J, Steklac KE, Ramsey M, Bayer KU, Herson PS, Quillinan N. Calcium/Calmodulin-Dependent Kinase (CaMKII) Inhibition Protects Against Purkinje Cell Damage Following CA/CPR in Mice. Mol Neurobiol. 2020 Jan; 57(1):150-158.
    View in: PubMed
    Score: 0.105
  10. Barcomb K, Goodell DJ, Arnold DB, Bayer KU. Live imaging of endogenous Ca??/calmodulin-dependent protein kinase II in neurons reveals that ischemia-related aggregation does not require kinase activity. J Neurochem. 2015 Nov; 135(4):666-73.
    View in: PubMed
    Score: 0.079
  11. Thein S, Pham A, Bayer KU, Tao-Cheng JH, Dosemeci A. IKK regulates the deubiquitinase CYLD at the postsynaptic density. Biochem Biophys Res Commun. 2014 Jul 18; 450(1):550-4.
    View in: PubMed
    Score: 0.073
  12. Turecek J, Yuen GS, Han VZ, Zeng XH, Bayer KU, Welsh JP. NMDA receptor activation strengthens weak electrical coupling in mammalian brain. Neuron. 2014 Mar 19; 81(6):1375-1388.
    View in: PubMed
    Score: 0.072
  13. Vest RS, O'Leary H, Coultrap SJ, Kindy MS, Bayer KU. Effective post-insult neuroprotection by a novel Ca(2+)/ calmodulin-dependent protein kinase II (CaMKII) inhibitor. J Biol Chem. 2010 Jul 02; 285(27):20675-82.
    View in: PubMed
    Score: 0.055
  14. Vest RS, O'Leary H, Bayer KU. Differential regulation by ATP versus ADP further links CaMKII aggregation to ischemic conditions. FEBS Lett. 2009 Nov 19; 583(22):3577-81.
    View in: PubMed
    Score: 0.053
  15. Bayer KU, LeBel E, McDonald GL, O'Leary H, Schulman H, De Koninck P. Transition from reversible to persistent binding of CaMKII to postsynaptic sites and NR2B. J Neurosci. 2006 Jan 25; 26(4):1164-74.
    View in: PubMed
    Score: 0.041
  16. Leonard AS, Bayer KU, Merrill MA, Lim IA, Shea MA, Schulman H, Hell JW. Regulation of calcium/calmodulin-dependent protein kinase II docking to N-methyl-D-aspartate receptors by calcium/calmodulin and alpha-actinin. J Biol Chem. 2002 Dec 13; 277(50):48441-8.
    View in: PubMed
    Score: 0.032
  17. Bayer KU, De Koninck P, Leonard AS, Hell JW, Schulman H. Interaction with the NMDA receptor locks CaMKII in an active conformation. Nature. 2001 Jun 14; 411(6839):801-5.
    View in: PubMed
    Score: 0.030
  18. Deng G, Orfila JE, Dietz RM, Moreno-Garcia M, Rodgers KM, Coultrap SJ, Quillinan N, Traystman RJ, Bayer KU, Herson PS. Autonomous CaMKII Activity as a Drug Target for Histological and Functional Neuroprotection after Resuscitation from Cardiac Arrest. Cell Rep. 2017 01 31; 18(5):1109-1117.
    View in: PubMed
    Score: 0.022
  19. Yang Y, Tao-Cheng JH, Bayer KU, Reese TS, Dosemeci A. Camkii-mediated phosphorylation regulates distributions of Syngap-a1 and -a2 at the postsynaptic density. PLoS One. 2013; 8(8):e71795.
    View in: PubMed
    Score: 0.017
  20. Tao-Cheng JH, Yang Y, Bayer KU, Reese TS, Dosemeci A. Effects of CaMKII inhibitor tatCN21 on activity-dependent redistribution of CaMKII in hippocampal neurons. Neuroscience. 2013 Aug 06; 244:188-96.
    View in: PubMed
    Score: 0.017
  21. Illario M, Cavallo AL, Bayer KU, Di Matola T, Fenzi G, Rossi G, Vitale M. Calcium/calmodulin-dependent protein kinase II binds to Raf-1 and modulates integrin-stimulated ERK activation. J Biol Chem. 2003 Nov 14; 278(46):45101-8.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)